Ensysce Biosciences (ENSC) Issues Mid-Year 2024 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Ensysce Biosciences Provides Mid-Year 2024 Update
July 23, 2024 10:32 AM EDT~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~
~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~
~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough... More



